Acute Myeloid Leukemia (AML) Treatment

Acute myeloid leukemia is an aggressive blood cancer that begins in the bone marrow. It occurs when immature white blood cells (myeloblasts) undergo harmful changes that cause them to grow uncontrollably. The abnormal cells then crowd out healthy cells and spill into the bloodstream, interfering with the production of mature white blood cells, normal red blood cells and platelets.

In the United States, AML is one of the most frequently diagnosed types of acute leukemia in adults, with several thousand new cases identified each year. Because the cancer may develop suddenly and advance rapidly, a prompt evaluation and timely treatment are essential.

Management of acute myeloid leukemia is individualized based on several key factors, including the patient’s age and overall health, the specific chromosomal and molecular characteristics of the cancer and how it responds to initial treatment. Care is typically delivered in structured phases and may involve chemotherapy, targeted therapy, immunotherapy, bone marrow transplantation, radiation therapy or enrollment in a clinical trial, depending on the patient’s unique diagnosis and treatment goals.

Chemotherapy for acute myeloid leukemia

For many patients with AML, treatment begins with chemotherapy, which is typically delivered in two stages: induction and consolidation. Induction therapy aims to destroy as many leukemia cells as possible and restore normal blood cell production. Consolidation therapy then follows to eliminate any remaining cancer cells and lower the risk of relapse.

What is the role of chemotherapy in acute myeloid leukemia treatment?

Chemotherapy is a cornerstone of AML treatment. In many cases, it is the first-line therapy used to control the cancer and achieve remission. Because acute myeloid leukemia often progresses quickly, chemotherapy is usually intensive and designed to work rapidly. Induction therapy frequently requires a hospital stay to allow for close monitoring, transfusions and supportive care as needed. Consolidation therapy may include additional cycles of chemotherapy, sometimes using different medications than those given during induction.

Common chemotherapy regimens for acute myeloid leukemia

The chemotherapy drugs used to treat AML work in different ways. Some interfere with DNA replication, while others disrupt cell division or damage the internal structure of the leukemia cells. A commonly used induction regimen is known as 7+3, which combines cytarabine given over seven days with an anthracycline, such as daunorubicin or idarubicin, given during the first three days.

Additional chemotherapy drugs, including fludarabine, cladribine or etoposide, may be used in certain cases. The most appropriate chemotherapy regimen depends on several factors, including the AML subtype, the molecular features of the leukemia and the patient’s overall risk profile.

What are the potential risks and side effects of chemotherapy for acute myeloid leukemia?

Because chemotherapy for AML is intensive, it can cause a range of side effects. These may include:

• Severe fatigue
• Low blood cell counts that increase the risk of infection
• Nausea or vomiting
• Mouth sores
• Hair loss
• Easy bleeding and bruising

Supportive treatments such as antibiotics, transfusions and anti-nausea medications are routinely used during chemotherapy to help manage the side effects and support patient comfort.

Preparation and recovery from chemotherapy for acute myeloid leukemia

Before chemotherapy begins, the patient will undergo thorough testing to help guide treatment planning. This evaluation may include blood tests, heart function assessments and genetic or molecular analyses of the leukemia cells.

Recovery after induction therapy often takes several weeks, as the bone marrow needs time to resume producing healthy blood cells. Recovery time between consolidation cycles can vary depending on the treatment approach and how the patient responds to therapy.

Rated High Performing in Leukemia, Lymphoma & Myeloma

Recognized in U.S. News & World Report's Best Hospitals for significantly better performance in leukemia, lymphoma and myeloma treatment than the national average.

Schedule an Appointment

Targeted therapy for acute myeloid leukemia

Advances in genetic testing have made it possible to identify specific mutations that drive the growth of AML. Targeted therapies are designed to block these mutations or interfere with the pathways leukemia cells rely on to survive and multiply.

Some targeted medications focus on mutations such as FLT3, IDH1 or IDH2, which are present in certain AML subtypes. These therapies are often used in combination with chemotherapy and may also be an option for a patient whose leukemia does not respond to standard treatment or returns after initial therapy.

How does targeted therapy for acute myeloid leukemia work?

Targeted drugs act on specific proteins or molecular pathways that are altered in AML cells. By inhibiting these signals, the medications can slow or stop cancer cell growth while limiting any effects on healthy cells.

When is targeted therapy considered for acute myeloid leukemia?

Targeted therapy may be recommended for AML if genetic testing identifies a mutation that can be treated with a specific medication. Some targeted therapies are used at the time of diagnosis as part of the initial treatment plan, while others may be introduced if the cancer does not respond to standard therapies or returns after treatment. Eligibility for targeted therapy also depends on factors such as the patient’s overall health, prior treatments and specific characteristics of the leukemia.

What are the potential risks and side effects of targeted therapy for acute myeloid leukemia?

Targeted therapy may cause side effects. Although these medications are designed to focus on cancer-specific mutations or pathways, they can sometimes affect some normal cells as well.

Targeted drugs for AML work by blocking proteins or signaling pathways that leukemia cells use to grow and survive. In some cases, those same pathways are also involved in normal cellular functions, such as cell growth, digestion or liver metabolism. When these pathways are disrupted, side effects can occur.

The side effects of targeted therapy often differ from those seen with chemotherapy and may be more limited. They can also vary depending on the specific drug used and how the patient’s body responds. Common experiences include:

• Fatigue
• Diarrhea
• Swelling in the legs or abdomen
• Fever
• Nausea
• Changes in liver function

Many side effects of targeted therapy are manageable with dose adjustments or supportive care. During treatment, the patient will undergo regular blood tests and close monitoring to help ensure the prescribed drug regimen remains effective.

Preparation and recovery from targeted therapy for acute myeloid leukemia

Before starting targeted therapy, the patient will undergo genetic testing to determine whether a targeted medication is available and appropriate for their specific type of AML. Many targeted drugs are taken daily and may be administered on an outpatient basis. In some cases, targeted therapy is combined with chemotherapy as part of a broader treatment plan.

Treatment duration and recovery can vary, and the patient will be monitored closely through regular clinic visits and blood tests to assess the response and manage any side effects.

Immunotherapy for acute myeloid leukemia

Immunotherapy uses the body’s immune system to help identify and eliminate leukemia cells. Unlike chemotherapy, which directly destroys rapidly dividing cells, or targeted therapy, which blocks specific genetic mutations, immunotherapy works by enhancing the immune system’s natural ability to fight cancer.

For AML, immunotherapy options may include monoclonal antibodies, antibody-drug conjugates and treatments that help immune cells recognize specific markers on leukemia cells. These approaches may be used for certain AML subtypes, as part of a combination treatment strategy or when the cancer does not respond to standard therapies.

How does immunotherapy work?

Immunotherapy works by strengthening or redirecting the body’s immune response so it can better recognize and eliminate cancer cells. Some treatments attach to the leukemia cells and mark them for destruction, while others enhance or modify the immune cells to help them target the cancer more effectively.

When is immunotherapy considered for acute myeloid leukemia?

Immunotherapy may be considered for AML if the leukemia characteristics suggest it could be beneficial and the condition does not respond to initial treatment or returns after remission. Depending on the situation, immunotherapy may be used alone or in combination with other therapies.

How is immunotherapy administered?

Immunotherapy is typically given through intravenous infusions in an outpatient clinic or hospital setting. During an infusion, the medication is delivered through a vein over a period of time, which may range from less than an hour to several hours, depending on the drug. The patient will be monitored closely during and after the infusion for any immediate side effects.

Some immunotherapy medications can also be administered as injections. The timing and frequency of treatment can vary based on the specific drug and whether it is used alone or in combination with other therapies.

What are the potential risks and side effects of immunotherapy for acute myeloid leukemia?

Because immunotherapy activates the immune system, it can cause side effects, particularly early in treatment as the body adjusts. Common experiences include:

• Fever and chills
• Nausea
• Fatigue
• Lowered blood cell counts
• Infusion reactions
• Increased risk of infection

Many side effects of immunotherapy occur shortly after treatment begins and can be managed with supportive care and close monitoring.

Preparation and recovery from immunotherapy for acute myeloid leukemia

Before immunotherapy begins, the patient will undergo blood testing and may receive premedications to help reduce the risk of infusion-related reactions. Any side effects usually improve over time as treatment progresses. Throughout therapy and recovery, the healthcare team will monitor the patient closely to track their response, address side effects and ensure the treatment is well tolerated.

Bone marrow transplantation (BMT) for acute myeloid leukemia

BMT may be considered for a patient with intermediate-risk, high-risk or relapsed AML. This intensive treatment replaces damaged bone marrow with healthy blood-forming cells, helping restore the body’s ability to produce normal blood cells.

Two main types of bone marrow transplantation may be used to treat acute myeloid leukemia. An allogeneic transplant, which uses blood-forming cells derived from a compatible donor, is the most common approach for AML. An autologous transplant, which uses the patient’s own blood-forming cells, is used less often in select situations.

When is bone marrow transplantation considered for acute myeloid leukemia?

A bone marrow transplant may be recommended if the risk of AML relapse is high or remission has been achieved, but long-term cancer control remains uncertain. In general, a good candidate may be a patient who is healthy enough to tolerate this intensive treatment, such as a relatively young person in good overall health.

What does bone marrow transplantation for acute myeloid leukemia involve?

The bone marrow transplant process includes several key steps. First, the patient will receive high-dose chemotherapy to destroy the damaged bone marrow and suppress the immune system. This preparative treatment will be followed by an infusion of healthy blood-forming cells from a matched donor or, in some cases, from the patient. After the infusion, the patient will be monitored closely to ensure the new blood-forming cells engraft and begin producing normal blood cells.

What are the potential benefits and risks of bone marrow transplantation for acute myeloid leukemia?

BMT can offer the possibility of long-term remission or cure for some patients with AML, particularly those at higher risk of relapse. By replenishing the damaged bone marrow with healthy blood-forming cells, transplantation can allow the body to resume normal blood cell production and, in the case of an allogeneic transplant, may provide an enhanced immune effect that can help eliminate any remaining leukemia cells.

Because bone marrow transplantation involves intensive chemotherapy and rebuilding the immune system, it also carries significant risks. These may include serious infections, graft-versus-host disease (GVHD), organ dysfunction and a prolonged recovery. Close monitoring, infection prevention measures and comprehensive supportive care will be essential throughout treatment and recovery to help manage these risks and support patient safety.

Radiation therapy for acute myeloid leukemia

Radiation therapy uses high-energy beams, such as X-rays, to destroy cancer cells in a targeted area of the body. It is not commonly used as a primary treatment for acute myeloid leukemia, which is often widespread throughout the bone marrow and bloodstream at the time of diagnosis. However, this precise form of treatment can play an important role in specific situations as part of a broader care plan.

What is the role of radiation therapy for acute myeloid leukemia?

Radiation therapy delivers focused treatment to a defined area of the body. In AML, it may be used to treat leukemia cells that have formed a localized mass (chloroma) or to address cancer in a specific region, such as the brain or spine. Radiation therapy may also be used to shrink an enlarged organ that is causing symptoms or as part of the preparation process before a bone marrow transplant.

What are the potential risks and side effects of radiation therapy for acute myeloid leukemia?

The side effects of radiation therapy can vary depending on the part of the body treated and the dose used. Common issues include fatigue and nausea, along with localized skin reactions, such as redness, irritation or temporary swelling near the treatment site. When radiation therapy is delivered to limited areas in short courses, it is generally well tolerated. The healthcare team will monitor the patient closely and provide supportive care to help manage any side effects during treatment.

Clinical trials for acute myeloid leukemia

Clinical trials are designed to evaluate the effectiveness of emerging treatment approaches, such as novel chemotherapy drugs and combinations, next-generation targeted therapies, innovative immunotherapy strategies and advanced bone marrow transplant techniques.

A patient with AML might consider participating in a clinical trial at the time of diagnosis, after relapse or if standard treatments are not effective. These important research studies follow strict safety guidelines and allow patients to benefit from promising new therapies that are not yet widely available. Clinical trial participation can also help expand the scientific knowledge base and may improve AML care for future patients.

Benefit from world-class care at Moffitt Cancer Center

Acute myeloid leukemia requires rapid, coordinated care from a team of specialists who understand the complexities of this fast-moving disease. At Moffitt, we carefully evaluate each patient using advanced diagnostic tools, molecular profiling and detailed clinical examinations. Following this comprehensive assessment, we develop an individualized treatment strategy with input from hematologic oncologists, bone marrow transplant experts, pathologists, radiologists and supportive care providers.

Each week, our leukemia team meets to review challenging or evolving cases and ensure all treatment decisions reflect the latest research and best practices. This collaborative model allows us to adapt treatments as needed and offer therapies tailored to each patient’s cancer subtype, genetic features and overall goals. Working together, we help each patient achieve the best possible outcome and quality of life.

If you would like to explore your treatment options for acute myeloid leukemia with a specialist in the Malignant Hematology Program at Moffitt, you can request an appointment by calling 1-888-663-3488 or submitting a new patient registration form online. We do not require referrals.